Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition.
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition.